



**Procter & Gamble Hygiene
and Health Care Limited**
CIN: L24239MH1964PLC012971
Registered Office:
P&G Plaza
Cardinal Gracias Road, Chakala
Andheri (E), Mumbai 400 099
Tel: (91-22) 6958 6000
Fax: (91-22) 6958 7337
Website: in.pg.com

January 30, 2026

To,
The Corporate Relations Department
The BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001
Ref:- Scrip Code:- 500459

To,
The Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai - 400051
Ref:- Scrip Code:- PGHH

Dear Sir / Madam,

**Sub:- Unaudited Financial Results for the quarter ended December 31, 2025 and Interim
Dividend for Financial Year 2025-26**

We are pleased to inform you that at a meeting of the Board of Directors of the Company held today (commenced at 12:54 P.M. and ended at 01:57 P.M.), the Unaudited Financial Results for the quarter ended December 31, 2025 were approved.

We are enclosing herewith the following:

- a. Unaudited Financial Results for the quarter ended December 31, 2025; and
- b. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended December 31, 2025, furnished by Statutory Auditors of the Company.

Further, we are pleased to inform you that the Board of Directors of the Company at its meeting held today, inter alia, have declared an Interim Dividend for the Financial Year 2025-26 of Rs. 195 per Equity Share (including a one-time special dividend of Rs. 25 per Equity Share). The dividend shall be paid on or before February 27, 2026.

The Company has fixed the record date for the purpose of eligibility for payment of said Interim Dividend shall be February 5, 2026.

Kindly take the same on record.

Thanking you,
Yours faithfully,

For Procter & Gamble Hygiene and Health Care Limited

Flavia Machado
Authorized Signatory

**KALYANIWALLA
& MISTRY LLP**

CHARTERED ACCOUNTANTS

**REVIEW REPORT
TO THE BOARD OF DIRECTORS
PROCTER & GAMBLE HYGIENE AND HEALTH CARE LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **PROCTER & GAMBLE HYGIENE AND HEALTH CARE LIMITED** ("the Company") for the quarter and nine months ended December 31, 2025 and the notes thereon, ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, duly initialled by us for identification. This Statement which is the responsibility of the Company's Management has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on January 30, 2026, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant Rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
4. Attention is drawn to Note 4 regarding the fact that the Statement includes the results for the corresponding nine months ended December 31, 2024, which is arrived at by adding the published audited figures for the quarter ended June 30, 2024, on which we had issued an unmodified opinion vide our audit report dated August 28, 2024, and the published unaudited figures for the six months ended December 31, 2024, on which we had issued a separate limited review report dated February 11, 2025, which was unmodified.

For KALYANIWALLA & MISTRY LLP
CHARTERED ACCOUNTANTS
Firm Reg. No.: 104607W / W100166


Darius Z. Fraser
PARTNER

M. No. 042454

UDIN: **26042454MWRCXG12425**

Mumbai: January 30, 2026.

LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001
TEL.: (91) (22) 6158 6200, 6158 7200 FAX: (91) (22) 6158 6275



Procter & Gamble Hygiene
and Health Care Limited
CIN : L24239MH1964PLC012971
Registered Office: P&G Plaza
Cardinal Gracias Road, Chakala
Andheri (E), Mumbai 400 099
Tel: (91 - 22) 6958 6000
Fax: (91 - 22) 6958 7337
Website: in.pg.com

Particulars	₹ in Lakhs)					
	(1) Three Months Ended 31st December 2025	(2) Preceding Three Months Ended 30th September 2025	(3) Corresponding Three Months Ended 31st December 2024	(4) Nine Months Ended 31st December 2025	(5) Corresponding Nine Months Ended 31st December 2024	(6) Previous Year Nine Months Ended 31st March 2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited) (Refer Note 4 below)	(Audited) (Refer Note 3 below)
1 Income						
Sale of products	1 25 991	1 14 885	1 24 625	3 34 392	3 30 641	3 36 811
Other operating revenues	199	132	138	518	813	631
2 Revenue from operations	1 26 190	1 15 017	1 24 763	3 34 910	3 31 454	3 37 442
3 Other income	1 241	990	971	3 000	2 552	3 734
Total income (2+3)	1 27 431	1 16 007	1 25 734	3 37 910	3 34 006	3 41 176
4 Expenses						
a) Cost of raw and packing materials consumed	20 554	19 749	19 782	56 743	56 867	56 722
b) Purchases of stock-in-trade (Traded goods)	21 660	21 164	24 604	63 072	69 466	67 289
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(17)	3 607	(471)	1 019	(2 260)	1 500
d) Employee benefits expense	6 167	4 859	6 617	15 861	19 381	17 605
e) Finance costs	267	360	662	634	850	1 430
f) Depreciation and amortization expense	950	928	989	2 787	3 499	3 194
g) Impairment losses	—	—	—	—	1 303	—
h) Advertising & sales promotion expenses	14 548	17 597	15 834	39 018	48 464	45 244
i) Other expenses	23 098	19 585	21 304	63 924	60 228	61 976
Total expenses	87 227	87 829	89 321	2 43 058	2 57 828	2 54 960
5 Profit before tax (2+3-4)	40 204	28 178	36 413	94 852	76 178	86 216
6 Income tax expense						
a) Current tax	10 210	7 419	8 974	24 292	20 261	22 136
b) Deferred tax	(6)	(227)	423	(153)	(392)	(249)
c) Prior year tax adjustments	(146)	—	157	376	154	670
7 Profit for the period (5-6)	10 058	7 192	9 554	24 515	20 023	22 557
8 Other comprehensive income / (loss)	30 146	20 986	26 859	70 337	56 155	63 659
Items that will not be reclassified to profit or loss:						
Remeasurement of the defined benefit plans	160	557	(870)	481	(871)	(943)
Income tax effect on above	(40)	(140)	218	(121)	219	237
Total other comprehensive income / (loss) for the period	120	417	(652)	360	(652)	(706)
9 Total comprehensive income for the period (7+8)	30 266	21 403	26 207	70 697	55 503	62 953
10 Paid-up equity share capital (Face Value ₹ 10 per equity share)	3 246	3 246	3 246	3 246	3 246	3 246
11 Other Equity						
12 Earnings per Share (Face value of ₹ 10 per equity share) (not annualised) :						
a) Basic (in ₹)	92.87	64.65	82.74	216.68	172.99	196.11
b) Diluted (in ₹)	92.87	64.65	82.74	216.68	172.99	196.11
See accompanying notes to the financial results						



Notes:

- 1 The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on January 30, 2026, and have been subjected to a limited review by the Statutory Auditors of the Company. These financial results are prepared and published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2 The Unaudited Financial Results are prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS-34), as prescribed under Section 133 of the Companies Act, 2013, read with relevant Rules issued thereunder and other accounting principles generally accepted in India.
- 3 The Board of Directors of the Company, on January 23, 2025, approved the change of the previous Financial Year end from June 30th to March 31st. Accordingly, the previous Financial Year of the Company viz., 2024-25 was for a period of nine months commencing on July 1, 2024, and ended on March 31, 2025.
- 4 Pursuant to the change in the Financial Year as mentioned in note 3 above, the figures for the corresponding nine months ended December 31, 2024, are arrived at by adding the published audited figures for the quarter ended June 30, 2024, and the published unaudited figures for the six months ended December 31, 2024.
- 5 The Company's operating segments under Ind AS 108 – Operating Segments are as follows:
 - Health Care Products – Comprising of Ointment and Creams, Cough Drops and Tablets.
 - Hygiene Products – Comprising of Feminine Hygiene products and other skin care hygiene.
 These individual operating segments have been aggregated into a single primary reportable segment i.e. manufacturing, trading and marketing of Health and Hygiene Products in accordance with Ind AS 108-Operating Segments. Accordingly, separate segment information has been provided.
- 6 The Board of Directors at its meeting held on January 30, 2026, has declared for the current year an interim dividend of Rs. 195 per equity share (including a one-time special dividend of Rs. 25 per equity share) having nominal value of Rs. 10 per equity share, aggregating to Rs. 63298 Lakhs.
- 7 The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes viz the Code on Wages, 2019, the Code on Social Security, 2020, the Industrial Relations Code, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "Labour Codes"). The Labour Codes have been made effective from November 21, 2025. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations.
- 8 The Company has evaluated the impact of the Labour Codes on the basis of information currently available. Management has assessed that the incremental impact, if any, of these changes is not expected to be material given that the current salary structure of the Company is in line with the requirements of the Labour Codes. The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Codes and would make appropriate adjustments, if needed.
- 9 The Company does not have a subsidiary, associate or a joint venture as at December 31, 2025.

For and on behalf of the Board of Directors of
Procter & Gamble Hygiene and Health Care Limited

KUMAR
VENKATASU
BRAMANIAN
Dipaloy signed by
KUMAR
VENKATASU
BRAMANIAN
Date 2026/01/30 11:14:26
-05:30

Kumar Venkatasubramanian
Managing Director

Place: Mumbai
Date: January 30, 2026

